Evidence map›Paper›PMID 35999382›Full record

ArticleJournal of human hypertension2023

Resistant hypertension is associated with an increased cardiovascular risk compared to patients controlled on a similar multi-drug regimen.

Adi Leiba, Naama Yekutiel, Gabriel Chodick, Joshua Wortsman, Avital Angel-Korman, Baruch Weinreb

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of human hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Adi LeibaInstitute of Nephrology and Hypertension, Assuta Ashdod University Hospital, Faculty of Health Sciences, Ben Gurion University, Beer Sheva, Israel. drleiba@gmail.com.ORCID http://orcid.org/0000-0002-5420-299X
Naama YekutielMaccabitech Institute for Research & Innovation, Maccabi Healthcare Services, Tel Aviv, Israel.
Gabriel ChodickMaccabitech Institute for Research & Innovation, Maccabi Healthcare Services, Tel Aviv, Israel.
Joshua WortsmanMaccabitech Institute for Research & Innovation, Maccabi Healthcare Services, Tel Aviv, Israel.
Avital Angel-KormanInstitute of Nephrology and Hypertension, Assuta Ashdod University Hospital, Faculty of Health Sciences, Ben Gurion University, Beer Sheva, Israel.
Baruch WeinrebFaculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba, Israel.
Ben-Gurion University of the Negev · ILMaccabi Institute for Health Services Research · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The long-term risk associated with resistant hypertension compared to other phenotypes of hypertension is still unclear. We aimed to assess cardiovascular and renal outcomes over 10 years of follow-up of patients with uncontrolled resistant hypertension (uRH) compared to a similarly treated (≥ 3 medication classes including a diuretic) and adherent group whose blood pressure is under control. This retrospective cohort study utilized the computerized database of Maccabi Healthcare Services, a state-mandated health provider covering 25% of the Israeli population. Clinical outcomes were assessed using Cox regression multivariable analyses. A total of 1487 patients (50% males, mean age at baseline = 68.3 ± 10.4 years) were included in the uRH cohort and 1343 patients (50% males, 66.2 ± 10.6 years) in the controlled hypertension reference group (Controlled hypertension on multi drug regimen- CH-MDR). After adjusting for age, sex, BMI and patients' comorbidities, uRH was associated with a Hazard Ratio of 1.35 (95% CI: 1.08-1.69) for incidence of ischemic heart disease, 1.51 (1.06-2.16) for secondary cardiovascular events, and 1.36 (1.00-1.86) for risk of stroke or transient ischemic attack compared to the reference group. Patients with uRH were found to have more hospitalization days (mean, 4.2 vs. 3 days per year, p < 0.001), and more emergency room visits (83.3% vs. 77%, p < 0.001). Overall, uRH was associated with a 19% (95% CI 11% to 29%) increase in direct healthcare expenditures during the first year of follow-up. uRH is associated with a substantial increased risk of both cardiovascular and cerebrovascular events, when compared to similarly treated hypertensive patients whose blood pressure is under control.

Indexed as

Cardiovascular DiseasesHypertensionStrokeAntihypertensive AgentsBlood PressureFemaleHeart Disease Risk FactorsHumansMaleRetrospective StudiesRisk FactorsAntihypertensive Agents

Identifiers

PMID35999382
OpenAlexW4293089515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.